Medexus Pharmaceuticals Inc. (CVE:MDP – Get Free Report)’s share price traded down 4.9% on Monday . The company traded as low as C$7.70 and last traded at C$7.75. 40,981 shares traded hands during trading, a decline of 40% from the average session volume of 68,619 shares. The stock had previously closed at C$8.15.
Analyst Ratings Changes
Separately, Stifel Nicolaus decreased their price objective on Medexus Pharmaceuticals from C$2.85 to C$2.35 in a research report on Thursday, February 22nd.
Read Our Latest Stock Analysis on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Down 4.9 %
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older.
Read More
- Five stocks we like better than Medexus Pharmaceuticals
- What is Insider Trading? What You Can Learn from Insider Trading
- The 3 Hottest Insiders Buys This Month
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- How to Choose Top Rated Stocks
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.